Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to predict dangerous blood clots in cancer patients on chemo

NCT ID NCT07196020

Knowledge-focused Sponsor: University of Dublin, Trinity College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

Cancer patients face a higher risk of blood clots during chemotherapy, but it's hard to know who is most at risk. This study will measure clotting-related biomarkers in the blood of 380 patients with ovarian, lung, stomach, or pancreatic cancer at four points during their treatment. By comparing those who develop clots with those who don't, researchers hope to develop a blood test that predicts clot risk and helps guide the safe use of blood thinners.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test that identifies which cancer patients are at high risk of blood clots during chemotherapy, allowing doctors to use blood thinners more safely and effectively.
What could go wrong
This is an observational study, not a treatment trial. It is still in early stages and may not produce a reliable prediction tool. The results may not apply to all cancer types or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 380 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a diagnosis of ovarian, lung, gastric or pancreatic cancer who are scheduled to undergo a course of chemotherapy in the three study centres in Ireland.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with a diagnosis of ovarian, lung, gastric or pancreatic cancer scheduled to undergo a course of chemotherapy who are undergoing adjuvant or neoadjuvant chemotherapy, or who are undergoing chemotherapy for relapsed disease or patients receiving targeted therapy in combination with chemotherapy * Patients who are over 18 years of age * Patients who are able to give full and informed written consent Exclusion Criteria: * Prior history of a documented VTE event within the last 5 years (excluding central line associated events whereby patients completed anticoagulation \> 3 months previously) * Any history of significant haemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 5 years * Familial bleeding diathesis * Known diagnosis of disseminated intravascular coagulation. * Surgery within 2 weeks of first baseline sample (with the exception of porth-a-cath implantation or biopsy) * Chemotherapy or immunotherapy 4 weeks before first baseline sample * Currently receiving long term anticoagulant therapy (Low Molecular Weight Heparin(LMWH), Direct Oral Anticoagulants(DOACs), Warfarin). Patients receiving aspirin, ticlopidine, clopidogrel or LMWH at a prophylactic dosage for a short period (ie post cancer surgery or during short hospital stay) will be included provided they have completed thromboprophylaxis therapy at the first blood sampling time point.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer gastric cancer lung cancer malignant pancreatic neoplasm neoplasm ovarian cancer venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Venous thromboembolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cork University Hospital

    RECRUITING

    Cork, Ireland, T12 DC4A, Ireland

  • Mater Misericordiae University Hospital

    RECRUITING

    Dublin, Ireland, D07R2WY, Ireland

  • Trinity Cancer St. James Cancer Institute

    RECRUITING

    Dublin, Ireland, D08W9RT, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.